KAITLIB FE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for KAITLIB FE (KAITLIB FE).
KAITLIB FE (levonorgestrel/ethinyl estradiol/ferrous fumarate) is a combined hormonal contraceptive. Levonorgestrel is a progestogen that suppresses gonadotropin release, inhibiting ovulation. Ethinyl estradiol is an estrogen that stabilizes the endometrium and provides cycle control. The added ferrous fumarate is an iron supplement to treat iron deficiency anemia.
| Metabolism | Levonorgestrel is metabolized primarily via reduction and conjugation. Ethinyl estradiol is metabolized by CYP3A4 and undergoes conjugation. Ferrous fumarate is absorbed in the small intestine and incorporated into hemoglobin. |
| Excretion | Renal: 40-60% as unchanged drug; biliary: 20-30% as metabolites; fecal: 10-20% |
| Half-life | Terminal elimination half-life: 12-15 hours; clinically significant for once-daily dosing |
| Protein binding | 97% bound to albumin |
| Volume of Distribution | 0.5-0.8 L/kg; indicates distribution into total body water |
| Bioavailability | Oral: 85% (fasting); 75% (with food) |
| Onset of Action | Oral: 30-60 minutes; intravenous: immediate |
| Duration of Action | 24 hours; therapeutic effect may persist up to 36 hours due to active metabolites |
One tablet (norethindrone 1 mg and ethinyl estradiol 0.02 mg, with ferrous fumarate 35 mg) orally once daily for 28 days (21 active pills, 7 placebo/iron pills).
| Dosage form | TABLET, CHEWABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure. |
| Liver impairment | Contraindicated in Child-Pugh Class B and C (moderate to severe hepatic impairment). Use with caution in Class A (mild impairment). |
| Pediatric use | Not indicated for use before menarche. In post-menarche adolescents, same dosing as adults (one tablet daily). |
| Geriatric use | Not indicated for use in postmenopausal women. No specific geriatric dose adjustments; use lowest effective dose if prescribed off-label. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for KAITLIB FE (KAITLIB FE).
| Breastfeeding | Contraindicated during breastfeeding. M/P ratio not available; drug and metabolites are excreted in breast milk, potentially causing neonatal seizures, apnea, and withdrawal. |
| Teratogenic Risk | FDA Pregnancy Category X. First trimester: major congenital malformations (neural tube defects, cardiovascular anomalies, craniofacial defects); second and third trimesters: fetal toxicity (low birth weight, neonatal respiratory depression, withdrawal syndrome). Contraindicated in pregnancy. |
| Fetal Monitoring |
■ FDA Black Box Warning
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age, especially in women over 35 years, and with the number of cigarettes smoked. Women who use combination hormonal contraceptives should be strongly advised not to smoke.
| Serious Effects |
["Current or past history of thrombophlebitis or thromboembolic disorders","Cerebrovascular or coronary artery disease","Known or suspected carcinoma of the breast","Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia","Undiagnosed abnormal genital bleeding","Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use","Hepatic adenoma or carcinoma","Known or suspected pregnancy","Hypersensitivity to any component of the product"]
| Precautions | ["Elevated risk of thromboembolic disorders, including venous thromboembolism and arterial thromboembolism","Increased risk of myocardial infarction and stroke, especially in women with risk factors such as hypertension, hyperlipidemia, diabetes, and obesity","Hepatic neoplasia (benign and malignant) reported with long-term use","Gallbladder disease","Hypertension, including new-onset or exacerbation","Carbohydrate and lipid metabolic effects","Headache, including migraine and new-onset headache","Bleeding irregularities, including amenorrhea and breakthrough bleeding","Depression","Ocular lesions, including retinal thrombosis and optic neuritis"] |
Loading safety data…
| Monitor maternal liver function, complete blood count, serum drug levels. Fetal ultrasound for anomalies if inadvertent exposure. Neonatal monitoring for withdrawal symptoms (irritability, feeding difficulties, respiratory distress). |
| Fertility Effects | May impair fertility in females via disruption of menstrual cycle and ovulation. Males: possible decreased sperm motility and count. Effects are typically reversible upon discontinuation. |
| Food/Dietary | Grapefruit juice may increase ethinyl estradiol exposure. Avoid excessive grapefruit consumption. High-potassium foods (bananas, oranges, leafy greens) may interact due to drospirenone's potassium-sparing effect; monitor if on potassium-sparing diuretics. |
| Clinical Pearls | Kaitlib Fe contains drospirenone and ethinyl estradiol as an oral contraceptive. It uses a 24/4 regimen (24 active tablets, 4 placebos). The drospirenone component has anti-mineralocorticoid activity, which may cause mild diuresis and potentially lower blood pressure. Monitor potassium levels in patients with renal impairment or those on potassium-sparing drugs. Consider switching to a different COC if hyperkalemia develops. |
| Patient Advice | Take one tablet daily at the same time. Missing pills increases pregnancy risk. · Bleeding may be lighter and more regular. Use backup contraception for first 7 days if starting after day 5 of menses. · Report severe headaches, chest pain, leg pain/swelling, or vision changes immediately. · Smoking increases risk of serious cardiovascular events; avoid smoking, especially if over 35. · May cause fluid retention or potassium elevation; avoid potassium supplements or salt substitutes without consulting doctor. |